CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-22). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1154 · Search date 2026-07-22 · Methodology v0.6

Radium-223 dichloride,
does it really help with Prolonged overall survival and delayed symptomatic skeletal events in castration-resistant prostate cancer with symptomatic bone metastases and no visceral metastases?

30-Second Summary
A
Evidence Grade A · 93 · Safety unknown
Radium-223 prolongs survival and delays the first symptomatic skeletal event in castration-resistant prostate cancer with symptomatic bone metastases and no visceral metastases
What the
research shows
Radium-223 is rated A because a large double-blind randomized trial showed prolonged overall survival and delayed the first symptomatic skeletal event in castration-resistant prostate cancer with symptomatic bone metastases and no visceral metastases. In the final analysis of 921 ALSYMPCA participants, median overall survival was 14.9 versus 11.3 months, with a death hazard ratio of 0.70; a prespecified follow-up analysis found 15.6 versus 9.8 months to the first symptomatic skeletal event, hazard ratio 0.66. Both mortality and clinically apparent skeletal events improved, supporting A with 93 points. Myelosuppression, gastrointestinal adverse effects, and fractures remain separate safety issues; concurrent initiation with abiraterone and prednisone or prednisolone increased fractures to 29% versus 11% without improving efficacy in the separate ERA 223 trial and should be avoided.
What the
ads claim
A 3.6-month difference in median survival does not mean every individual lives exactly 3.6 months longer, nor does targeting bone metastases mean cure. Although radium-223 emits alpha particles, it should not be presented as a general systemic radiotherapy for visceral or soft-tissue disease.
*

Useful facts when choosing a product

  • Radium-223 is a prescription radiopharmaceutical that behaves similarly to calcium, localizes to areas of increased bone formation in metastases, and emits short-range alpha particles.
  • The ALSYMPCA regimen used up to six intravenous injections at four-week intervals, while the administered activity should follow current calibrated product labeling and nuclear-medicine protocols.
  • Blood counts should be checked before treatment and each dose, with treatment held or stopped when anemia, thrombocytopenia, or neutropenia does not recover adequately.
  • Fracture risk and bone health should be assessed and bone-protecting therapy considered; concurrent initiation with abiraterone and prednisone or prednisolone is not recommended because of increased fractures.
Gap Measurement · Verdict 1154 · A 93
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Parker and colleagues in ALSYMPCA administered six injections of radium-223 or placebo at four-week intervals to patients who had received docetaxel, were ineligible for it, or declined it. The trial stopped early for efficacy at a prespecified interim analysis, and the 921-participant updated analysis retained a death hazard ratio of 0.70 and a 3.6-month median survival difference. The follow-up analysis by Sartor and colleagues assessed clinically apparent symptomatic skeletal events, defined by external-beam radiation for bone pain, symptomatic pathologic fracture, spinal-cord compression, or tumor-related orthopedic surgery rather than periodic imaging alone, and found significant delay. The pathologic-fracture component alone was not confirmed, with a hazard ratio of 0.62 and 95% CI of 0.35 to 1.09. Separate ERA 223 findings in asymptomatic or mildly symptomatic patients showed that adding radium-223 concurrently to abiraterone and a steroid did not improve skeletal-event-free survival and increased fractures, making strict separation of population, regimen, efficacy, and safety essential.

02

Why this is classified as A (93)

In the 921-participant double-blind ALSYMPCA trial, median overall survival was 14.9 versus 11.3 months with a death hazard ratio of 0.70, and median time to the first symptomatic skeletal event was 15.6 versus 9.8 months with a hazard ratio of 0.66. Although evidence is concentrated in one program, the hard-mortality-endpoint exception to the manufacturer ceiling and corpus alignment with grade-A prostate-cancer survival evidence support A with 93 points. Myelosuppression, fracture, and combination risks remain separate safety issues.

Counterpoint. Benefit applies most directly to castration-resistant disease with symptomatic bone metastases and no known visceral metastases. Reduction of pathologic fractures alone was not confirmed, and the evidence should not be extended to asymptomatic disease, visceral metastases, or hazardous combinations.

Rejudgment record. New verdict — Applied grade A for median overall survival of 14.9 versus 11.3 months with a direct death hazard ratio of 0.70 in the 921-participant double-blind ALSYMPCA phase 3 trial and prespecified time to first symptomatic skeletal event of 15.6 versus 9.8 months with a hazard ratio of 0.66; applied the hard-endpoint exception to the manufacturer ceiling for a prescription radiopharmaceutical and corpus alignment with grade-A prostate-cancer survival evidence

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Prolonged overall survival in castration-resistant prostate cancer with symptomatic bone metastases and no visceral metastasesAThe final ALSYMPCA analysis showed a direct mortality benefit, with median survival of 14.9 versus 11.3 months and a death hazard ratio of 0.70.
Delayed first symptomatic skeletal eventAClinically apparent events rather than scheduled-imaging surrogates were delayed to 15.6 versus 9.8 months, with a hazard ratio of 0.66.
Reduction of symptomatic pathologic fracture aloneDThe ALSYMPCA component hazard ratio was 0.62 with a 95% CI of 0.35 to 1.09, so efficacy for pathologic fracture alone was not confirmed.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1International randomized double-blind placebo-controlled phase 3 trial921Algeta and Bayer HealthCare PharmaceuticalsPrimary overall survival and key secondary clinical outcomesFinal median overall survival was 14.9 versus 11.3 months, with a death hazard ratio of 0.70 (95% CI 0.58 to 0.83; P<0.001).Pivotal large randomized trial with a direct mortality endpoint
Study 2Prespecified secondary clinical-endpoint analysis of ALSYMPCA307Algeta and Bayer HealthCare PharmaceuticalsTime to first symptomatic skeletal event and clinical componentsMedian time was 15.6 versus 9.8 months, hazard ratio 0.66 (95% CI 0.52 to 0.83); pathologic fracture alone had a hazard ratio of 0.62 (95% CI 0.35 to 1.09).Direct clinical support for symptomatic skeletal events
Study 3Randomized double-blind placebo-controlled phase 3 trial of concurrent abiraterone and steroid therapy806BayerSymptomatic skeletal-event-free survival and fracture safetyThere was no benefit in symptomatic skeletal-event-free survival, hazard ratio 1.122, while fractures increased to 29% versus 11%.Combination efficacy and safety limitation
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-22).

Parker C, Nilsson S, Heinrich D, et al.; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-223. PMID: 23863050. DOI: 10.1056/NEJMoa1213755.
checked
Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15(7):738-746. PMID: 24836273. DOI: 10.1016/S1470-2045(14)70183-4.
checked
Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):408-419. PMID: 30738780. DOI: 10.1016/S1470-2045(18)30860-X.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-22 · Corrections: none

Cite this verdict

Radium-223 dichloride x prolonged survival and delayed skeletal events in symptomatic bone-metastatic castration-resistant prostate cancer without visceral metastases Evidence Grade A card
[Chamgap] Radium-223 dichloride x prolonged survival and delayed skeletal events in symptomatic bone-metastatic castration-resistant prostate cancer without visceral metastases — Evidence Grade A·93. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/radium-223-symptomatic-bone-metastatic-castration-resistant-prostate-cancer-survival-skeletal-events/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.